Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

Timeline

Start

2023-07-31

Primary completion

2024-07-15

Completion

2024-12-13

Outcome

Met primary endpoint

registry analysis (superiority test); Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID; p <0.0001; Odds Ratio (OR) 9.82 (95% CI 4.48 to 21.49) NCT05906628 ↗

Drugs

Indications